Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Congress Sounds Alarm: China’s Deepening Control Over US Drug Supply Poses National Security Risk

by Team Lumida
November 18, 2025
in Macro
Reading Time: 4 mins read
A A
0
U.S. Struggles to Break China’s Grip on Critical Minerals as Syrah Resources Faces Setbacks
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • China supplies key ingredients for roughly 25% of generic drugs used in the US—including some produced exclusively in China.
  • A congressional report warns that China could weaponize pharmaceutical supply chains, similar to its rare-earth restrictions.
  • The FDA currently lacks authority to track where core drug ingredients are made, leaving policymakers blind to the full extent of dependency.
  • China is rapidly expanding from generics into innovative biotech, synthetic biology, and early-stage drug development—deepening US reliance.

What Happened?

A new report from the US-China Economic and Security Review Commission warns that America’s pharmaceutical supply chain is far more dependent on China than the government can currently measure. One-quarter of US generic drugs rely on Chinese-made ingredients, and for some critical medicines—including antibiotics, blood thinners, and cancer drugs—China is the only global source. The FDA does not have legal authority to track manufacturing origins for active pharmaceutical ingredients (APIs), leaving policymakers unable to fully quantify the risk. Simultaneously, China is expanding aggressively into cutting-edge drug development and synthetic biology, strengthening its control over multiple layers of the pharmaceutical ecosystem.


Why It Matters?

The findings signal a major national security and health-security vulnerability. A disruption—deliberate or accidental—in Chinese pharmaceutical output could trigger severe shortages in the US, forcing hospitals to ration lifesaving treatments. For investors, the report underscores structural risks across the healthcare and biotech sectors, including supply shocks, higher costs, and regulatory intervention. China’s growing leadership in synthetic biology and early-stage drug development also increases competitive pressure on US biotech firms, many of which partner with China due to cost advantages. Legislative scrutiny is rising, and Washington appears poised to impose new disclosure requirements, restrict certain partnerships, and incentivize reshoring of pharmaceutical manufacturing.


What’s Next?

Congress is expected to pursue legislation requiring drugmakers to disclose the origins of all key ingredients, giving the FDA visibility it currently lacks. The administration is also evaluating ways to reduce biotech dependence on China, potentially through incentives for domestic manufacturing, tighter control over licensing deals, and revised FDA fee structures to nudge more early-stage research back into the US. However, reshoring generics production will be expensive, slow, and challenging—especially since even India and Europe rely heavily on Chinese-sourced APIs. Investors should watch for regulatory shifts affecting biotech partnerships, rising production costs, and emerging bipartisan efforts to build a more resilient US drug supply chain.

Source
Previous Post

The Hidden Cost of “Leaving China”: Why US Manufacturers Face a Harder-Than-Expected Supply Chain Pivot

Next Post

Jeff Bezos Reenters the Arena: Bringing Amazon-Era Playbook to a $6.2 Billion AI Startup

Recommended For You

Bessent Says Treasury, Defense and State Backed Blacklisting Megaspeed ‘for Months,’ and Blames Commerce for Nvidia Chip ‘Leakage’

by Team Lumida
2 days ago

Treasury Secretary Bessent said several departments backed blacklisting Megaspeed for months, and he called Nvidia chip leakage to China “very frustrating.”

Read more

October PPI Rises 0.3%, but the Annual Rate Hits 6.5%, the Highest Since November 2022, as Goolsbee Says the Fed Has ‘Work to Do’

by Team Lumida
2 days ago

October PPI rose 0.3%, but the annual rate hit 6.5%, a nearly four-year high, as Chicago Fed President Goolsbee said the Fed has work to do.

Read more

10-Year Treasury Yield Hits 5.174% After the PPI Report, as Traders Price a December Fed Hike as a Certainty

by Team Lumida
2 days ago

The 10-year Treasury yield reached 5.174% on Friday and was at 5.143%, as traders priced 100% odds of a Federal Reserve rate increase on Dec. 9.

Read more

87% of Fed Survey Respondents Now Cite AI as a Salient Financial-System Risk, Up From 50% in the Spring

by Team Lumida
2 days ago

A Federal Reserve survey released Friday found 87% of respondents cited AI as a salient risk to the financial system, up from 50% in the spring.

Read more

10-Year Treasury Yield Edges Up 2 Basis Points to 5.01% as Cash Bond Trading Resumes After Veterans Day

by Team Lumida
4 days ago

The 10-year Treasury yield rose 2 basis points to 5.01% as cash bond trading resumed after Veterans Day, with PPI and home sales due.

Read more

Huang’s Scandal Revives a Push to Put New China Chip Curbs in the NDAA Ahead of Next Week’s Trump-Xi Summit

by Team Lumida
4 days ago

Huang’s scandal is reviving a push to put new China chip curbs in this year’s defense bill, days before a planned Trump-Xi meeting.

Read more

Goolsbee Calls October CPI ‘Borderline Disturbing’ and Puts Everything ‘on the Table,’ While Voter Paulson Says Only Gradual Fed Tightening Is Needed for Now

by Team Lumida
5 days ago

Goolsbee called October’s CPI ‘borderline disturbing,’ while Philadelphia Fed voter Paulson said gradual tightening still seems appropriate for now.

Read more

US Credit Card Balances Hit a Record $1.29 Trillion as Growth Slows to 4.2% and Serious Delinquencies Hold Near 12.9%, New York Fed Says

by Team Lumida
5 days ago
US Credit Card Defaults Surge to Post-2008 Highs, Signaling Consumer Stress

Credit card balances rose 4.2% to a record $1.29 trillion in the third quarter as household debt hit $19.1 trillion, while card delinquencies steadied.

Read more

Fed’s Bowman Turns Her Focus to Inflation After a Hot 0.4% CPI but Stops Short of Backing a December Hike, as Logan and Waller Push Harder

by Team Lumida
5 days ago

Bowman said ‘there is still work to do’ on inflation after a 0.4% CPI print but held off backing a December hike, as Logan and Waller urged tightening.

Read more

Waller Says Skipping Promised Fed Hikes Would Loosen Policy ‘in an Undesirable Way,’ Opening the Door to a Half-Point Move in December

by Team Lumida
5 days ago

Fed Governor Waller said the Fed must deliver the hikes markets expect, leaning toward a December increase and backing 50 basis points if inflation runs hot.

Read more
Next Post
Jeff Bezos Cashes In: Sells $5 Billion in Amazon Shares After Record High

Jeff Bezos Reenters the Arena: Bringing Amazon-Era Playbook to a $6.2 Billion AI Startup

Bitcoin Plunges to $64K Amid U.S. Tech Stock Turmoil

Bitcoin ETF Boom Turns Sour as Prices Fall Below Investors’ $89,600 Break-Even Level

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

top-view photography of houses at daytime

Homeownership Costs Skyrocket 26% Since Pandemic

June 10, 2024
Ripple Adds Stripe-Owned Privy Wallets to XRP Ledger; AI Agent Payments Reach 14.3M Transactions but Total Value Under $600K Raises Questions About Economic Substance

HSBC Says Ripple’s 24/7 Stock Swaps Need Depth First, and Saturday’s $52 Million Chip-Stock Wipeout Showed Why

October 21, 2026
Gates Foundation Pledges $1 Billion for AI Equity as Bill Gates Warns of Widening Rich-Poor Divide

Gates Foundation Pledges $1 Billion for AI Equity as Bill Gates Warns of Widening Rich-Poor Divide

September 15, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018